QMS Medical Allied Services Ltd
QMS Medical Allied Services Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue, margins and capex.
Top 10 Healthcare Equipment & Supplies companies on management guidance
See the sector's top 10 — free with your mobile number.
What the Q1 FY27 call signalled
1 of 2 strong
The short version
QMS expects continued growth in patient support programs (PSP) contributing INR90-105 crores revenue in FY27, driven by expanded contracts and new initiatives. The company expects an uptick in performance over the earlier quarters to continue, with average margins projected to be higher by the end of FY27, aiming around 16%-20% EBITDA margin.
From QMS Medical Allied Services Ltd's Q1 FY27 earnings-call transcript · updated 11 Sept 2026.
Revenue & Sales Performance
- QMS expects continued growth in patient support programs (PSP) contributing INR90-105 crores revenue in FY27, driven by expanded contracts and new initiatives.
- Product business growth is supported by Q Devices, targeting 20-25% of total product revenue within 3 years, with 17+ products currently launched and more in the pipeline.
- Service revenue, including PSP and camps, is increasing with a higher contribution to margins due to strategic focus.
- B2B health camps increased 40% YoY, supporting early diagnosis and awareness, expected to continue scaling.
- The company aims to maintain around INR220 crores top-line guidance for FY27, with potential upward revision post Q2/Q3.
2 more points from QMS Medical Allied Services Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what QMS Medical Allied Services Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Emphasis is placed on scaling the service business, particularly patient service programs (PSPs), expanding the product business led by Q-Devices and Point of Care Solutions.
- The company plans to grow Q-Devices product offerings from 17 products currently, targeting 20-25% of total product revenue from Q-Devices within 3 years, implying investment in product development and technology.
- Focus on leveraging technology across the healthcare ecosystem for scalable, measurable, and data-driven service delivery suggests strategic investment in technology platforms.
- Hiring plans are aligned with contractual wins, indicating careful operational investment rather than large upfront capex.
Top-ranked in Healthcare Equipment & Supplies
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what QMS Medical Allied Services Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- PSPs typically operate on annual contracts with renewals toward year-end; hence, a specific "order book" is not defined in the traditional sense.
- PSP contracts are cost-plus with markup; employee and admin costs are passed to clients, so hiring aligns with contract commitments.
- Current PSP revenue run rate suggests strong growth, with INR17 crores in Q1 FY27 and an expected INR90-105 crores for the full year.
- Contract renewals historically exhibit a 60-70% roll-over rate annually, ensuring revenue visibility from existing clients.
2 more points from QMS Medical Allied Services Ltd's call on order book
Create a free account to keep reading this call
QMS Medical Allied Services Ltd — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹37 Cr, net profit ₹3 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What QMS Medical Allied Services Ltd's management said in earlier quarters
Others in Healthcare Equipment & Supplies this season
- Nureca Ltd (Q1 FY27)
Revenue from Operations for Q1 FY'27: ₹40.3 Cr . Key investor presentation takeaways from Nureca's Q1 FY27 investor presentation — and how it ranks against sect
- Avience Biomedicals Ltd (Q1 FY27)
New manufacturing facility has capacity to support peak revenue of around ₹250–265 crore, subject to product mix and approvals. Key concall takeaways from…
- Fischer Medical Ventures Ltd (Q1 FY27)
The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…
- Molbio Diagnosti (Q1 FY27)
Capacity utilization currently at ~58% for test kits and ~42% for devices; automation capex will double revenue capacity with minimal new investment. Key…
Potential multibaggers · Q2 FY27
Potential multibaggers in Healthcare Equipment & Supplies
on management's own guidance
- Strong growth2
- Strong growth1
- Q-Line BiotechGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
QMS Medical Allied Services Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were QMS Medical Allied Services Ltd Q1 FY27 results?
QMS expects continued growth in patient support programs (PSP) contributing INR90-105 crores revenue in FY27, driven by expanded contracts and new initiatives. The company expects an uptick in performance over the earlier quarters to continue, with average margins projected to be higher by the end of FY27, aiming around 16%-20% EBITDA margin.
What is QMS Medical Allied Services Ltd share price analysis?
QMS Medical Allied Services Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 28.6 with a market cap of ₹307 Cr. Investors should review the full earnings analysis for detailed insights.
Keep QMS Medical Allied Services Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.